Enclomiphene vs Telmisartan
Well Studied vs FDA Approved
avoid Mechanism-based · 64% Both Enclomiphene and Telmisartan carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
Enclomiphene Telmisartan
Weight 405.96 Da 514.62 Da
Half-life ~10 hours ~24 hours
Type Trans-isomer of clomifene (selective estrogen receptor modulator) Benzimidazole derivative (C33H30N4O2)
Key Benefits
Enclomiphene
01 Raises endogenous testosterone by stimulating the HPTA axis
02 Preserves fertility and spermatogenesis (unlike exogenous testosterone)
03 No estrogenic agonist activity (unlike racemic clomifene/Clomid)
04 Oral dosing with no injections required
05 Does not suppress the HPTA or cause testicular atrophy
06 Effective for post-cycle therapy and secondary hypogonadism
07 Well-tolerated with a favorable side effect profile
Telmisartan
01 Potent 24-hour blood pressure reduction with once-daily dosing
02 Protection against AAS-induced left ventricular hypertrophy and cardiac remodeling
03 Nephroprotection through reduced intraglomerular pressure and proteinuria
04 Unique partial PPAR-gamma agonism improving insulin sensitivity and lipid metabolism
05 No negative impact on exercise performance, VO2 max, or recovery
06 Reduction of pathological vascular remodeling and arterial stiffness
07 Longest half-life of all ARBs ensuring consistent 24-hour coverage
08 Well-tolerated with a low incidence of side effects compared to ACE inhibitors (no dry cough)
Side Effects
Enclomiphene
Headache
Nausea or mild gastrointestinal discomfort
Hot flashes or flushing
Mood changes (irritability or emotional sensitivity)
Fatigue during initial adjustment
Telmisartan
Dizziness or lightheadedness, particularly during the first few days or after dose increases
Mild hypotension, especially in volume-depleted individuals or those on concurrent antihypertensives
Upper respiratory tract infection symptoms (sinusitis, pharyngitis) - reported in clinical trials at rates similar to placebo
Back pain and myalgia (uncommon but reported)
Fatigue
Contraindications
Known hypersensitivity to clomifene or enclomiphene
Pre-existing liver disease or significantly elevated liver enzymes
Active or history of thromboembolic disorders
Pregnancy or women who may become pregnant (teratogenic risk)
Primary hypogonadism (testicular failure -- enclomiphene requires functional testes)
Pituitary tumors or undiagnosed pituitary pathology
Pregnancy (Category D - can cause fetal injury and death; discontinue immediately if pregnancy is detected)
Bilateral renal artery stenosis
Known hypersensitivity to telmisartan or any excipients
Concurrent use with aliskiren in patients with diabetes or renal impairment (eGFR <60)
Severe hepatic impairment or biliary obstruction (telmisartan is eliminated primarily via biliary excretion)
Research Evidence
Enclomiphene Telmisartan
Status Well Studied FDA Approved
References 5 studies 5 studies
Latest — 2023
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.